Navigation Links
Mylan Restores Availability of Generic Levothyroxine in Florida
Date:2/8/2008

PITTSBURGH, Feb. 8 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today announced that Mylan Pharmaceuticals Inc. has obtained an order from an administrative law judge in Florida finding that the inclusion of Levothyroxine Sodium on the state's negative drug formulary is an invalid exercise of legislative authority and that the product should be removed from the negative formulary.

Mylan will make its products available to pharmacies in Florida as soon as motions and procedural steps surrounding its removal from the negative formulary are satisfied. Florida's Board of Medicine and Board of Pharmacy voted not to appeal the Jan. 28, 2008, order; Abbott Laboratories has filed a formal appeal.

When a drug is included on Florida's negative formulary, pharmacists cannot substitute a generic version for a prescribed brand version. Florida pharmacists have been prohibited from substituting the generic version of Levothyroxine Sodium, depriving patients access to an affordable, effective and safe generic approved by the U.S. Food and Drug Administration.

In August 2007, Mylan filed a petition against Florida's Department of Health, Board of Pharmacy and Board of Medicine challenging the validity of Levothyroxine's inclusion on the negative formulary. Abbott Laboratories, maker of a brand version of Levothyroxine Sodium (Synthroid(R)), intervened. In an order issued Jan. 28, Mylan's subsequent motion for summary final order was granted.

"This ruling is not just a victory for Mylan, it's a major victory for the citizens of Florida who have been denied access to lower cost Levothyroxine Sodium for years," said Mylan's Chief Operating Officer Heather Bresch. "The state will benefit from tens of millions of dollars in savings as a result of this decision, and we are extremely pleased that the judge on this case saw through the brand company's baseless tactics to limit consumer access to affordable and effective medications."

Levothyroxine Sodium is indicated for the treatment of hypothyroidism and pituitary TSH suppression. According to IMS Health, more prescriptions are filled nationwide with Mylan's Levothyroxine Sodium tablets than any other Levothyroxine product, brand or generic. Mylan's version is the only generic product considered therapeutically equivalent to four brand versions, including Synthroid(R), Levoxyl(R), Levothroid(R) and Unithroid(R).

Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey, L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas. For more information about Mylan, please visit http://www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Mylan Announces Final FDA Approval for Carvedilol Tablets
3. Mylan Announces Tentative FDA Approval for Topiramate Capsules
4. Mylan Announces Appointment of M. Fabiana Lacerca as Senior Vice President and Chief Compliance Officer
5. Mylan Announces Extension of Tender Offers for Its 5.750% Senior Notes due 2010 and 6.375% Senior Notes due 2015
6. Mylan Announces Appointment of David A. Lillback as Senior Vice President and Global Head of Human Resources
7. Mylan Announces Appointment of Brian Byala as Senior Vice President and Treasurer
8. Mylan Announces Appointment of Didier Barret as President, Europe, Middle East and Africa
9. Mylan Announces Appointment of Harry A. Korman as President, North America
10. Mylan Announces Appointment of John Montgomery as President, Asia Pacific
11. Mylan Announces Management of Specialty Business, Dey L.P.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released ... understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture ... Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that is ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and ... of published author, William Nowers. Captain Nowers and his wife, Millie, have six ... years in the Navy. Following his career as a naval aviator and carrier ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the ... – Miles by Moonlight to raise money for the American Heart Association Heart Walk. ... , Teams will work together to keep their treadmills moving for 5 hours. Treadmills ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... , Oct. 11, 2017  True Health, ... has amplified its effort during National Breast Cancer ... hereditary cancer risks. ... Clinical Oncology calculated that more than 10 million ... inherited mutations in BRCA1 or BRCA2 and have not ...
(Date:10/10/2017)... --  West Pharmaceutical Services, Inc. (NYSE: WST), a ... today shared the results of a study highlighting the ... administration of polio vaccines. The study results were presented ... by Dr. Ondrej Mach , Clinical Trials and ... and recently published in the journal Vaccine. i ...
(Date:10/4/2017)... , Oct. 4, 2017  South Korean-based healthcare product ... training aide "cprCUBE" on Kickstarter. The device will educate ... cardiac arrests with better efficiency compared to the dated ... real-time feedback on efficacy of the compression for a ... has a goal to raise $5,000. ...
Breaking Medicine Technology: